Palvella Therapeutics officer sells 12,500 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Palvella Therapeutics, Inc. (PVLA) Chief Scientific Officer Jeffrey S. Martini exercised options for 12,500 common shares on November 10 and 11, 2026, at exercise prices of $7.53 and $9.79 per share. He also sold 12,500 common shares across those dates in multiple transactions. The exercises and sales were made under a Rule 10b5-1 trading plan adopted July 13, 2026.
Insider Trade Summary 10b5-1
Exercise and Sale: 12,500 shares ($1.97M approx. pre-tax spread)
Exercise and Sale
19 txns
Insider
Martini Jeffrey S
Role
Chief Scientific Officer
Sold
12,500 shs ($2.08M)
Approx. gross sale proceeds
$2.08M
Approx. exercise cost
$113K
Approx. pre-tax spread
$1.97M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F15 | 6,250 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 6,250 | $9.79 | $61K |
| Sale | Common Stock F1, F8 | 1,650 | $164.1422 | $271K |
| Sale | Common Stock F1, F9 | 1,467 | $165.7776 | $243K |
| Sale | Common Stock F1, F10 | 1,133 | $166.7626 | $189K |
| Sale | Common Stock F1, F11 | 1,200 | $167.7488 | $201K |
| Sale | Common Stock F1, F12 | 600 | $168.7333 | $101K |
| Sale | Common Stock F1, F13 | 200 | $169.7822 | $34K |
| Exercise | Stock Option (Right to Buy) F1, F14 | 4,266 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F1, F15 | 1,984 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 4,266 | $7.53 | $32K |
| Exercise | Common Stock F1 | 1,984 | $9.79 | $19K |
| Sale | Common Stock F1, F2 | 100 | $163.3353 | $16K |
| Sale | Common Stock F1, F3 | 1,449 | $164.8524 | $239K |
| Sale | Common Stock F1, F4 | 1,651 | $165.8472 | $274K |
| Sale | Common Stock F1, F5 | 1,500 | $166.9127 | $250K |
| Sale | Common Stock F1 | 200 | $167.81 | $34K |
| Sale | Common Stock F1, F6 | 550 | $169.0264 | $93K |
| Sale | Common Stock F1, F7 | 800 | $172.1188 | $138K |
Holdings After Transaction:
Stock Option (Right to Buy) — 36,141 options (Direct);
Common Stock — 0 shares (Direct)
Footnotes (15)
- F1. The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 13, 2026. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.12 to $163.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.42 to $165.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.62 to $166.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $166.63 to $167.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $168.82 to $169.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F7. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $171.83 to $172.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F8. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.77 to $164.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F9. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.25 to $166.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F10. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $166.25 to $167.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F11. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $167.32 to $168.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F12. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $168.48 to $169.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F13. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $169.49 to $169.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F14. The stock option vests in equal monthly installments over a forty-eight month period. The option was granted on May 28, 2024.
- F15. The stock option vests in equal monthly installments over a forty-eight month period. The option was granted on February 23, 2023.
Key Figures
Options exercised: 12,500 options
Common shares sold: 12,500 shares
Exercise price: $7.53 per share
+3 more
6 metrics
Options exercised
12,500 options
November 10 and 11, 2026
Common shares sold
12,500 shares
November 10 and 11, 2026
Exercise price
$7.53 per share
4,266 options exercised November 10, 2026
Exercise price
$9.79 per share
1,984 options exercised November 10, 2026, and 6,250 options exercised November 11, 2026
Rule 10b5-1 plan adoption
July 13, 2026
The plan was adopted during an open trading window.
Option vesting period
48 months
Options vested in equal monthly installments.
Key Terms
Rule 10b5-1 trading plan, weighted average price, vests in equal monthly installments
3 terms
Rule 10b5-1 trading plan regulatory
"pursuant to a Rule 10b5-1 trading plan adopted on July 13, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
vests in equal monthly installments financial
"The stock option vests in equal monthly installments over a forty-eight month period."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When were the PVLA options exercised by Jeffrey S. Martini granted, and how did they vest?
The exercised options included options granted May 28, 2024, and February 23, 2023. Each option vested in equal monthly installments over a 48-month period.
AI-generated analysis. How Rhea-AI works. Not financial advice.
